220 filings
PRE 14A
NTLA
Intellia Therapeutics Inc
Preliminary proxy
16 Apr 24
4:10pm
8-K
NTLA
Intellia Therapeutics Inc
15 Apr 24
Departure of Directors or Certain Officers
4:21pm
8-K
NTLA
Intellia Therapeutics Inc
22 Mar 24
Termination of a Material Definitive Agreement
9:26am
424B5
NTLA
Intellia Therapeutics Inc
26 Feb 24
Prospectus supplement for primary offering
7:04am
424B5
NTLA
Intellia Therapeutics Inc
23 Feb 24
Prospectus supplement for primary offering
5:22pm
8-K
8uvl1u2ifxkkbi
23 Feb 24
Amendment No. 1 to the Open Market Sale Agreementsm
5:17pm
S-8
5cd 7uikusbufy4zpd
22 Feb 24
Registration of securities for employees
4:11pm
8-K
i1qnhk 6c9jmd
22 Feb 24
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
7:45am
8-K
jdoagmyurn3lzdilgye
1 Feb 24
Regulation FD Disclosure
4:05pm
8-K
guvnayy45traohaa4lx
4 Jan 24
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
4:07pm
8-K
qy3ihs32hdn2
6 Dec 23
Departure of Directors or Certain Officers
7:00am
S-3ASR
8jnln7pu30sry9qs
24 Nov 23
Automatic shelf registration
9:30am
8-K
e83d9w
9 Nov 23
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:45am
8-K
r4b5zxml da5zfc4v9w
2 Nov 23
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
7:11am
8-K
jtlx7ary t5m6
18 Oct 23
Intellia Therapeutics Announces FDA Clearance of
7:30am
8-K
x5q 7vtuolyzrc0dom
3 Oct 23
Regeneron and Intellia Announce Expanded Research Collaboration
7:19am
8-K
7a5kqasv9e0 cfu
3 Aug 23
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:45am